Verastem/$VSTM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
- Ticker
- $VSTM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 102
- Headquarters
- Needham, United States
- Website
- www.verastem.com
Verastem Metrics
BasicAdvanced
$1.2B
-
-$2.28
0.32
-
Price and volume
Market cap
$1.2B
Beta
0.32
52-week high
$10.82
52-week low
$3.43
Average daily volume
4.6M
Financial strength
Current ratio
2.255
Quick ratio
2.119
Long term debt to equity
1.568
Total debt to equity
1.687
Interest coverage (TTM)
-108.19%
Profitability
EBITDA (TTM)
-158.647
Gross margin (TTM)
87.64%
Net profit margin (TTM)
-231.59%
Operating margin (TTM)
-182.57%
Effective tax rate (TTM)
-0.40%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
-49.59%
Return on equity (TTM)
-471.16%
Valuation
Price to revenue (TTM)
9.894
Price to book
17.66
Price to tangible book (TTM)
25.87
Price to free cash flow (TTM)
-5.04
Free cash flow yield (TTM)
-19.84%
Free cash flow per share (TTM)
-1.935
Growth
Revenue change (TTM)
3,995.74%
Earnings per share change (TTM)
-35.20%
3-year earnings per share growth (CAGR)
-19.71%
10-year earnings per share growth (CAGR)
-16.79%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Analyst projections of the future price of Verastem stock.
Bulls say / Bears say
AVMAPKI FAKZYNJA CO-PACK generated $25.1 million in net product revenue in Q2 2026, up from $18.7 million in Q1, pointing to growing commercial uptake of Verastem’s first approved product. (Verastem, Inc., Verastem, Inc.)
Two-year follow-up from the Phase 2 RAMP 201 study found median duration of response of 31.1 months and median progression-free survival of 12.9 months across KRAS-mutant and wild-type recurrent ovarian cancer. These results strengthen the case for the drug combination and its potential beyond the currently approved KRAS-mutant group. (Nasdaq)
Early VS-7375 data showed a 41% confirmed response rate among 22 patients with second-line-or-later pancreatic cancer, while the FDA has aligned with Verastem on a pivotal first-line trial design. If confirmed in larger studies, this oral KRAS G12D programme could add a substantial growth opportunity beyond the ovarian cancer franchise. (StockTitan, StreetInsider)
The ovarian-cancer drug’s FDA approval is accelerated and may depend on confirmation of clinical benefit. The Phase 3 RAMP 301 readout is not expected until 2027, leaving regulatory and efficacy risk unresolved for the core product. (Verastem, Inc., Investing.com)
Q2 operating expenses were $72.8 million against $25.1 million of product revenue, and Verastem’s stated cash runway only reaches into the second half of 2027. Continued trial expansion could therefore keep the company reliant on further financing before its pipeline matures. (Verastem, Inc.)
Verastem filed a preliminary offering of common shares and pre-funded warrants on 14 October, creating a near-term dilution risk for existing holders if completed. The filing had not yet set the offering size or price. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Upcoming events
No upcoming events
Verastem News
AllArticlesVideos
Funds containing Verastem
Fund name | Fund size | $VSTM weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.